Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Vilanterol 是一种长效的β2-AR 激动剂,效力持续24小时,能够作用于β2-AR (pEC50=10.37),β1-AR (pEC50=6.98) 和 β3-AR (pEC50=7.36)。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 342 | 待询 | ||
5 mg | ¥ 756 | 待询 | ||
10 mg | ¥ 1,110 | 待询 | ||
25 mg | ¥ 1,980 | 待询 | ||
50 mg | ¥ 3,341 | 待询 | ||
1 mL * 10 mM (in DMSO) | ¥ 797 | 待询 |
产品描述 | Vilanterol is a selective long-acting beta2-adrenergic agonist (LABA) used in the treatment of COPD and asthma. |
靶点活性 | β1-adrenoceptor:6.98±0.03(pEC50), β2-adrenoceptor:10.37±0.05(pEC50), β3-adrenoceptor:7.36±0.03(pEC50) |
体外活性 | The selectivity of Vilanterol for β2-AR over the other β-AR receptor subtypes (β2 and β3) is established by testing the ability of Vilanterol to elicit concentration-dependent increases in cAMP in CHO cells expressing human β1-, β2-, and β3-AR. Vilanterol is demonstrated to be highly selective for the β2-AR with at least a 1000-fold selectivity over both β2- and β3-AR subtypes. This analysis results in a low-affinity pKD for [3H]Vilanterol of 9.44±0.07 (n=4) in the presence Gpp(NH)p and a high-affinity pKD of 10.82±0.12 (n=4) and a low-affinity pKD 9.47±0.17 (n=4) in the absence of Gpp(NH)p. In addition, a low-affinity pKD for [3H]Vilanterol of 9.52±0.24 (n=4) in the absence of Gpp(NH)p (37°C) is observed[1]. Vilanterol trifenatate is a novel inhaled long-acting β2-agonist with inherent 24 h activity in vitro in development as a combination with the inhaled corticosteroid fluticasone furoate for both COPD and asthma[2]. Vilanterol is a novel long-acting β2-agonist (LABA) with inherent 24-hour activity for once-daily Clinicalal treatment of chronic obstructive pulmonary disease (COPD) and asthma in combination with the inhaled novel corticosteroid fluticasone furoate, also active for 24 hours[3]. |
激酶实验 | Saturation, association, and dissociation binding studies are performed for [3H]Vilanterol to determine receptor binding kinetics at the β2-AR (equilibrium dissociation constant (KD), total number of receptors (Bmax), association rate (kon), and dissociation rate (koff) are calculated). For saturation binding, membranes (in a volume of 1.4 mL to avoid ligand depletion) are incubated with increasing concentrations of [3H]Vilanterol (~0.01-1.3 nM) for 5 h before filtration. For association binding, membranes are incubated with different concentrations of [3H]Vilanterol (~0.1-1.9 nM) for varying incubation times up to 1 h before filtration. For dissociation binding, membranes are preincubated for 1 h with a fixed concentration of [3H]Vilanterol (~1.1 nM) before dissociation is initiated by a 1:20 dilution in binding buffer (containing 10 μM cold Vilanterol) and then incubated for varying times up to 8 h before filtration. Saturation binding is also completed for [3H]CGP12177 (increasing concentrations of ~0.01-2.8 nM) in the same format as described above for [3H]Vilanterol. To determine the affinity of β2-AR agonists and antagonists, competition binding displacement studies are completed in which membranes are incubated with a fixed concentration of [3H]Vilanterol (~0.2 nM) and increasing concentrations of unlabeled agonist/antagonist for 5 h before filtration. All competition binding displacement studies are completed in the presence of 100 μM Gpp(NH)p to ensure that binding curves are monophasic[1]. |
别名 | GW642444, 维兰特罗, GW642444X |
分子量 | 486.43 |
分子式 | C24H33Cl2NO5 |
CAS No. | 503068-34-6 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 50 mg/mL (102.79 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.0558 mL | 10.279 mL | 20.5579 mL | 51.3949 mL |
5 mM | 0.4112 mL | 2.0558 mL | 4.1116 mL | 10.279 mL | |
10 mM | 0.2056 mL | 1.0279 mL | 2.0558 mL | 5.1395 mL | |
20 mM | 0.1028 mL | 0.5139 mL | 1.0279 mL | 2.5697 mL | |
50 mM | 0.0411 mL | 0.2056 mL | 0.4112 mL | 1.0279 mL | |
100 mM | 0.0206 mL | 0.1028 mL | 0.2056 mL | 0.5139 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Vilanterol 503068-34-6 GPCR/G Protein Neuroscience Adrenergic Receptor inhibit GW642444 GW-642444 GW 642444 维兰特罗 GW642444X Beta Receptor Inhibitor inhibitor